Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Transfusion|March 25, 2017
Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpuraTanja Falter, Veronique Schmitt, Stephanie Herold, et al.
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on PharmacokineticsNicole Moschny, Gudrun Hefner, Renate Grohmann, et al.
Therapeutic Drug Monitoring|November 16, 2020
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic DrugsGeorgios Schoretsanitis, Pierre Baumann, Andreas Conca, et al.
Frontiers in Psychiatry|November 3, 2022
Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancyLuzie Eichentopf, Christoph Hiemke, Andreas Conca, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|June 24, 2024
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychoticsXenia Marlene Hart, Gerhard Gründer, Nicolas Ansermot, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 2, 2018
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians<sup/>Georgios Schoretsanitis, Michael Paulzen, Stefan Unterecker, et al.
Der Nervenarzt|November 18, 2018
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]Stefan Unterecker, Gudrun Hefner, Pierre Baumann, et al.
Pharmacopsychiatry|July 2, 2026
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspectsXenia M Hart, Gerhard Gründer, Christoph Hiemke, et al.
Pageof 3